OBJECTIVES: To develop an economic impact of BRCA1 and BRCA2 genetic tests in women with advanced stage ovarian cancer in the Colombian context. METHODS: Using the decision tree model, in a lifetime horizon, we analyzed the application of BRCA1 and 2 genetic tests in a hypothetical cohort of 100 patients diagnosed with this disease, taking into account the probability of positive or negative result according to the scientific evidence. At the same time, the prevalence and incidence of this disease was taken in order to find the probability of development or non-development of ovarian cancer in the relatives of these patients, for each patient with this disease, a family member at risk of developing ovarian cancer was associated according to the national household survey of the National Administrative Department of Statistics in Colombia, given the indication of the tests (Adelaida criteria). Drug costs (per minimum unit of presentation) and procedures were taken from databases of the Colombian health system, according to the management in clinical practice guidelines, which were corroborated by clinical experts. The cost of the tests was provided by the funder. A sensitivity analysis was performed based on the size change of the hypothetical cohort of the relatives. RESULTS: For a cohort of 100 patients the cost of applying the tests is USD $4,536,728 and not to do so is USD $4,587,387, with savings of USD $50,659 (USD $ 507 per patient) for its implementation. As the hypothetical cohort of relatives increased in the sensitivity analysis to 2 and 3, the savings per patient are USD $3,636 and USD $6,765 respectively. CONCLUSIONS: Given the savings in costs showed, it is concluded that it is important to implement the use of genetic tests in order to save costs of treatment of ovarian cancer and to prevent the late diagnosis of the disease.